Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Summary

Citius Oncology secured up to $36.5 million in debt and equity capital from Avenue Capital Group to accelerate commercialization of LYMPHIR®, comprising a $25 million senior credit facility and approximately $11.5 million from equity exercise.